Review Bombing Hits Drug Dealer Simulator Games Amid Copyright Dispute with Schedule 1
The *Drug Dealer Simulator* series is facing a wave of negative reviews on Steam following a copyright infringement investigation launched by its publisher, Movie Games S.A., against indie game *Schedule 1*. Fans of *Schedule 1* have expressed their frustration through review bombing, significantly impacting the lifetime user ratings of both *Drug Dealer Simulator* games.
Developed by Byterunners and published by Movie Games S.A., *Drug Dealer Simulator* and its 2024 sequel gained popularity after their respective releases in 2020 and 2024. Despite the first game holding a “Very Positive” rating on Steam, the recent backlash has caused a sharp decline in recent reviews, with 76% of the last 30 days’ reviews being negative. The sequel’s rating has also dipped into the “Mixed” category after a surge of critical feedback.
The review bombing is believed to be a reaction to Movie Games S.A.’s legal actions against *Schedule 1*, which launched on March 24. Many reviews accuse Movie Games of “bullying” the small indie team behind *Schedule 1* for creating a more successful game with a similar concept. This incident has drawn comparisons to other recent copyright disputes, including Nintendo’s ongoing legal battle with the developers of *Palworld*.
As the situation continues to unfold, *Drug Dealer Simulator* games’ ratings remain under scrutiny, with fans voicing their frustrations over the perceived hypocrisy of the publisher’s legal actions.
